Après-demain SA is a private, family-owned company based in Switzerland. It serves as the parent company of a group that consists of two divisions: the Life Sciences Division and the Asset Diversification Division. The Life Sciences Division, created by Dr.

Rolland-Yves Mauvernay in 1979, specializes in the development of innovative therapies in the fields of oncology and infectious diseases. Led by Dr. Mauvernay's son, Thierry Mauvernay, who joined in 2001, Debiopharm, a key part of the Life Sciences Division, aims to improve the patient treatment journey and make a positive impact on lives.

The Asset Diversification Division was established in the early 2000s to generate additional income and mitigate risks associated with Debiopharm's activities. It focuses on asset management with accountability, contributing to the improvement of the environment, education, nutrition, housing, leisure, and social services. In 2010, the group extended its support to various philanthropic projects, both locally and internationally.

Building on the group's success, a new division was created in 2020 that addresses the challenges of climate revolution and people living in precarious circumstances, known as Asset Management with Impact & Solidarity. Après-demain SA is committed to its shared values of agility, efficiency, passion, ethics, creativity, and commitment. With its dedication to making a difference, it continues to support sustainable growth and build a brighter future